Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis-Reference-Cited by-同舟云学术

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Published:2023-07-12 Issue:7 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sbidian Emilie¹²³,Chaimani Anna⁴⁵,Guelimi Robin¹³,Garcia-Doval Ignacio⁶,Hua Camille¹³,Hughes Carolyn⁷,Naldi Luigi⁸,Kinberger Maria⁹,Afach Sivem³,Le Cleach Laurence¹³

Affiliation:

1. Department of Dermatology; Hôpital Henri Mondor; Créteil France

2. Clinical Investigation Centre; Hôpital Henri Mondor; Créteil France

3. Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Université Paris Est Créteil (UPEC); Créteil France

4. Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France

5. Cochrane France; Paris France

6. Department of Dermatology; Complexo Hospitalario Universitario de Vigo; Vigo Spain

7. c/o Cochrane Skin Group; The University of Nottingham; Nottingham UK

8. Centro Studi GISED (Italian Group for Epidemiologic Research in Dermatology) - FROM (Research Foundation of Ospedale Maggiore Bergamo); Padiglione Mazzoleni - Presidio Ospedaliero Matteo Rota; Bergamo Italy

9. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin; Berlin Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference1156 articles.

1. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis;Griffiths;New England Journal of Medicine,2010

2. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients;Young;Expert Review of Clinical Immunology,2011

3. Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab;Blauvelt;United European Gastroenterology Journal,2017

4. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches;Blauvelt;British Journal of Dermatology,2018

5. Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and Humira (ADACCESS) clinicaltrials.gov/show/nct02016105

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intradermal Injection of a Thermoresponsive Polymeric Dexamethasone Prodrug (ProGel-Dex) Ameliorate Dermatitis in an Imiquimod (IMQ)-Induced Psoriasis-like Mouse Model;Molecular Pharmaceutics;2024-09-03

2. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

3. Head-to-Head-Studien bei Psoriasis und Psoriasisarthritis;Zeitschrift für Rheumatologie;2024-08-14

4. Short Term Efficacy of Biological Treatment for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis;2024-08-05

5. Master 2 award;Fundamental & Clinical Pharmacology;2024-06